Compare ERC & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ERC | ALEC |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 260.9M | 268.2M |
| IPO Year | N/A | 2019 |
| Metric | ERC | ALEC |
|---|---|---|
| Price | $8.97 | $2.21 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.83 |
| AVG Volume (30 Days) | 78.7K | ★ 524.3K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 8.37% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | N/A | ★ $21,045,000.00 |
| Revenue This Year | N/A | $2.03 |
| Revenue Next Year | N/A | $29.87 |
| P/E Ratio | $12.43 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.72 | $1.09 |
| 52 Week High | $9.78 | $3.40 |
| Indicator | ERC | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 41.26 | 47.32 |
| Support Level | $8.90 | $1.91 |
| Resistance Level | $9.33 | $2.62 |
| Average True Range (ATR) | 0.12 | 0.15 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 43.75 | 30.22 |
Allspring Multi-Sector Income Fund is a closed-end investment management company. The company's core business is to secure a high level of income for its investors consistent with limiting its overall exposure to domestic interest rate risk. It invests in U.S. dollar-denominated below investment-grade bonds, debentures, and other income obligations, including loans and preferred stocks, developed and emerging market debt securities, including obligations of foreign governments or governmental entities, foreign corporations, or supranational agencies denominated in various currencies, asset backed securities and investment grade corporate bonds.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.